Mahnel H, Mayr A
Lehrstuhl für Mikrobiologie und Seuchenlehre, Infektions- und Seuchenmedizin, Tierärztliche Fakultät der Universität München.
Berl Munch Tierarztl Wochenschr. 1994 Aug;107(8):253-6.
Immunizations against orthopox virus infections require a replicating, but safe vaccinia virus. The strain MVA is well suited concerning this matter. Human beings and animals can be vaccinated without any risk. The virus propagated in cell culture is non-virulent and lost its contagiosity. Multiplication in vaccinated men and animals is limited and excretion does not happen. As known for other attenuated virus strains, there must be a minimal effective virus concentration in the vaccine, which is 10(7.5) TCID50 per ml for MVA. To achieve a solid basic immunity which endures for a minimal of one year, two parenteral applications of MVA at intervals of at least 3 weeks are necessary.
针对正痘病毒感染的免疫接种需要一种具有复制能力但安全的痘苗病毒。MVA毒株在这方面非常合适。人类和动物接种该疫苗均无任何风险。在细胞培养中繁殖的这种病毒无毒力且失去了传染性。在接种疫苗的人和动物体内的繁殖受到限制，不会发生病毒排泄。正如其他减毒病毒株一样，疫苗中必须有最低有效病毒浓度，MVA的最低有效病毒浓度为每毫升10(7.5) 半数组织培养感染剂量（TCID50）。为了获得至少持续一年的稳固基础免疫力，需要至少间隔3周进行两次MVA的肠胃外接种。
